Oncternal Therapeutics Inc (ONCT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Oncternal Therapeutics Inc stock (ONCT) is currently trading at $0.53. Oncternal Therapeutics Inc PS ratio (Price-to-Sales) is 0.72. Analyst consensus price target for ONCT is $2.00. WallStSmart rates ONCT as Sell.
- ONCT PE ratio analysis and historical PE chart
- ONCT PS ratio (Price-to-Sales) history and trend
- ONCT intrinsic value — DCF, Graham Number, EPV models
- ONCT stock price prediction 2025 2026 2027 2028 2029 2030
- ONCT fair value vs current price
- ONCT insider transactions and insider buying
- Is ONCT undervalued or overvalued?
- Oncternal Therapeutics Inc financial analysis — revenue, earnings, cash flow
- ONCT Piotroski F-Score and Altman Z-Score
- ONCT analyst price target and Smart Rating
Oncternal Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Oncternal Therapeutics Inc (ONCT) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Oncternal Therapeutics Inc (ONCT) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Revenue surging 176.00% year-over-year
Supporting Valuation Data
Oncternal Therapeutics Inc (ONCT) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very low institutional interest at 12.07%
Micro-cap company with very limited liquidity and high volatility
Oncternal Therapeutics Inc (ONCT) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Revenue Growth. Valuation metrics including Price/Sales (0.72), Price/Book (0.17) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 176.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Institutional Own.. Profitability pressure is visible in Return on Equity at -149.90%, Operating Margin at -1757.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -149.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 176.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ONCT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ONCT's Price-to-Sales ratio of 0.72x trades at a deep discount to its historical average of 4.27x (32th percentile). The current valuation is 98% below its historical high of 42.29x set in Aug 2018, and 555% above its historical low of 0.11x in Mar 2016.
WallStSmart Analysis Synopsis
Data-driven financial summary for Oncternal Therapeutics Inc (ONCT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Oncternal Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 2M with 176% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 176% YoY, reaching 2M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 298% of revenue (6M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Oncternal Therapeutics Inc maintain 176%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Oncternal Therapeutics Inc.
Bottom Line
Oncternal Therapeutics Inc is a high-conviction growth story with revenue accelerating at 176% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:24:21 AM
About Oncternal Therapeutics Inc(ONCT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of cancer therapies for cancers with critical unmet medical needs. The company is headquartered in San Diego, California.